PAncreatic Adenocarcinoma in Hospital

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01989624

Acronym

APACH

Enrollment

1204

Registered

2013-11-21

Start date

2013-10-18

Completion date

2020-12-31

Last updated

2022-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Adenocarcinoma

Keywords

Pancreatic adenocarcinoma, diagnosis, treatment

Brief summary

Few data are currently available in the literature on pancreatic adenocarcinoma in France. About 8,000 new cases each year in France. The 5-year survival for all stages combined is \<5%. This is the only digestive cancer in which mortality / incidence ratio is 98%. Epidemiological characteristics at diagnosis, the impact on the survival of recent advances related to surgery, adjuvant chemotherapy and new standard forms of adjuvant chemotherapy (FOLFIRINOX) are mispriced in real life. The development of new drugs and the development of Phase II and III require a better understanding of the state of this disease in the country. The main objective is to describe the characteristics of the pancreatic adenocarcinoma at diagnosis in France and make an inventory of diagnostic practices and support.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Living in France * Pancreatic adenocarcinoma histologically or cytologically proven * primary diagnosis * Agreed to participate

Exclusion criteria

* Suspected pancreatic adenocarcinoma histologically or cytologically unproven * Refused to participate

Design outcomes

Primary

Measure	Time frame
Survival	patient death (following during 5 year)

Countries

Belgium, France

Outcome results